Philippe Martin

“We continue to execute with discipline across our pipeline and remain on track to deliver against our R&D priorities. Starting with our value-added medicines, the FDA review of our fast-acting Meloxicam NDA is substantially complete, with FDA being very engaged with us throughout the review process.”

“We have delivered a strong first half of the year in R&D as we continue to execute with discipline against our strategy. Starting with our value-added medicines, we were pleased to receive FDA approval for GreenLaw last week ahead of its PDUFA date.”

“Yeah, so, you know, I think, as you know, we are very proud of the data we've generated, in particular, the profile that emerged from the phase three program, rapid onset, strong efficacy, in line, if not better than opioid, and then that capacity to spare opioid use, right?”

“We've had a strong start of the year, continuing to advance our value-added and innovative portfolio. while executing on our generic pipeline. Let me begin with fast-acting meloxicam for the treatment of moderate to severe acute pain.”

“It's a real pleasure to have the opportunity to go over Viatris R&D capabilities and pipeline. So first, let me start by saying that in R&D, we look at our portfolio in three distinct areas.”